Asianet Newsable on MSN
Summit’s global lung cancer trials gain credibility after Akeso’s phase 3 data, says Guggenheim
Akeso reported positive late-stage data for Ivonescimab, a drug that Summit Therapeutics holds the rights to develop and sell outside China.
Summit Therapeutics (SMMT) gained in the premarket trading on Wednesday after announcing late-stage trial results that indicated that its lead asset, ivonescimab, licensed from Akeso (AKESF), ...
BioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we’ll get caught up with highlights from the annual meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results